Arjuna Capital Invests $2.25 Million in Sanofi (NASDAQ:SNY)

Arjuna Capital purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 38,952 shares of the company's stock, valued at approximately $2,245,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. POM Investment Strategies LLC bought a new stake in Sanofi in the 2nd quarter worth $25,000. Northwest Investment Counselors LLC purchased a new position in Sanofi in the third quarter worth about $29,000. Concord Wealth Partners grew its stake in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp bought a new stake in shares of Sanofi in the second quarter worth approximately $35,000. Finally, Fortitude Family Office LLC grew its position in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after buying an additional 659 shares during the period. Institutional investors own 10.04% of the company's stock.

Wall Street Analyst Weigh In

SNY has been the subject of a number of recent analyst reports. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi presently has an average rating of "Moderate Buy" and an average target price of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock traded down $0.63 during midday trading on Wednesday, hitting $49.51. The company had a trading volume of 1,680,688 shares, compared to its average volume of 2,026,771. The stock has a market cap of $125.65 billion, a price-to-earnings ratio of 25.30, a PEG ratio of 1.28 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $55.23 and a 200 day simple moving average of $52.25. Sanofi has a 12-month low of $45.13 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $2.55 EPS. As a group, analysts predict that Sanofi will post 4.27 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.